Alkermes rises on Q4 sales beat

Alkermes

12/02/2025 15:54

** Shares of drugmaker Alkermes  ALKS.O  rise 6.38% to $34 
    ** Co posts Q4 sales of $430 million, beating analysts'
estimate of $379 million - LSEG 
    ** Sees 2025 revenue between $1.3 billion and $1.4 billion
vs est $1.4 billion 
    ** Expects mid-stage study data of neurological disorder
drug in H2 2025
    ** Plans to begin early-stage study of drugs to treat sleep
disorders
    ** In the last 12 months, ALKS rose 7.6%

 (Reporting by Siddhi Mahatole)
 ((Siddhiprabhanjan.mahatole@thomsonreuters.com))